Q-omics provides the consensus-scored NUDT13 profile across patient tissues and cancer cell-line models. NUDT13 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, NUDT13 is differentially expressed in 7, with the highest sampling consensus in KICH. Additionally, NUDT13 RNA expression shows 20,922 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, KICH, and UVM as cancer lineages where NUDT13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NUDT13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NUDT13 survival associations across molecular data types. NUDT13 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NUDT13 RNA expression–survival associations across cancer types. High NUDT13 expression shows unfavorable associations in UVM and ACC, but favorable associations in MESO, READ, SKCM and KIRP. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for NUDT13 RNA expression.
This table summarizes NUDT13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for NUDT13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NUDT13 shows lower tumor expression in KICH, LUSC, THCA, BRCA, KIRP and HNSC. The KICH box plot shows higher NUDT13 RNA expression in normal versus tumor tissue (log2 FC = −1.631, t-test p < 0.001).
This table shows molecular features associated with NUDT13 in patient tissues and cancer cell lines. In patient samples, NUDT13 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, NUDT13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and CNS.
